Mexico Patient Adherence Programs Market Analysis

Mexico Patient Adherence Programs Market Executive Summary

The Mexico Patient Adherence Programs market is at around $194.3 Mn in 2023 and is projected to reach $628.3 Mn in 2030, exhibiting a CAGR of 18.25% during the forecast period.

A patient adherence program aims to ensure that patients follow prescribed medication regimens to improve treatment outcomes, using both direct and indirect methods to assess adherence. Direct methods include monitoring therapy by measuring drug levels, metabolites, or biological markers in blood or urine, and confirming medication intake. Indirect methods, more commonly used, involve patient self-reports, pill counts, prescription refill rates, clinical response evaluations, and electronic medication monitors. Pill counts compare the number of pills taken between appointments with the prescribed dosage, while patient self-reports collect information through interviews, questionnaires, or diaries. Electronic devices such as pill bottles or blister packs track medication access to provide precise data. A widely used tool for assessing adherence is the Morisky Medication Adherence Scale (MMAS), a validated and reliable questionnaire suitable for clinical use. These approaches help healthcare providers ensure consistent medication use, ultimately enhancing patient health outcomes.

The Mexico Patient Adherence Program Market is thus driven by significant factors such as increasing non-adherence, rising chronic conditions, and an aging population. However, inadequate healthcare infrastructure, high implementation costs, and limited accessibility restrict the growth and potential of the market.

The major players in the Mexico Patient Adherence Programs Market are Grupo Neolpharma, PiSA Farmaceutica, Liomont, Laboratorios Sanfer, and Laboratorios Sophia, among others.

Market Dynamics

Market Growth Drivers

Increasing Non-Adherence: The medical field is focusing more on developing workable solutions as a result of growing recognition of the substantial negative effects of non-adherence on patient outcomes. Governments and healthcare organizations’ awareness campaigns and actions highlight the value of adherence, which increases demand and growth for patient adherence programs.

Rising Chronic Conditions: Chronic diseases such as diabetes, hypertension, and heart disease require ongoing treatment and long-term medication adherence. The need for continuous monitoring and consistent medication use in chronic conditions necessitates adherence programs to ensure patients follow their prescribed regimens. Patient adherence programs lead to better clinical outcomes and enhanced quality of life, which creates a positive effect on the market growth.

Aging Population: Mexico’s population aged 65 and older is projected to grow by 277% from 8.2 Mn in 2015 to over 30 Mn by 2050. The elderly population is more prone to risk from chronic diseases and multiple comorbidities, necessitating complex medication regimens that are difficult to manage without structured adherence programs. Adherence programs help with polypharmacy and provide monitoring and support. The aging population is thus a potential pool that can benefit from these programs which increases the market growth.

Market Restraints

Inadequate Healthcare Infrastructure: By restricting access to vital healthcare services and resources required for these programs to be successful, inadequate healthcare infrastructure impedes the expansion of patient adherence initiatives. Patients face challenges in adhering to recommended therapies on a regular basis due to inadequate technology support, a lack of healthcare personnel, and poorly equipped facilities. Furthermore, inadequate infrastructure frequently results in healthcare practitioners' inability to adequately monitor and promote patient adherence, which has a negative impact on patient outcomes and diminishes confidence in these programs. As a result, these obstacles hinder market expansion by discouraging investments and limiting the efficacy and scalability of patient adherence programs.

High Implementation Costs: Establishing advanced technologies like electronic health records (EHRs), mobile health applications, telemedicine platforms, and electronic monitoring devices necessitates significant financial outlays. Additionally, the need to hire specialized personnel, such as IT experts, adherence counselors, and extra healthcare providers, adds to operational expenses. Integrating these new adherence technologies with existing healthcare systems and EHRs can be particularly complex and expensive. Thus, these all expenses related to patient adherence programs can negatively affect the market.

Limited Accessibility: Accessibility issues can hinder the expansion of the patient adherence program market, especially in regions with inadequate healthcare infrastructure. Patients in these areas often encounter obstacles like long travel distances to clinics, a scarcity of healthcare professionals, and limited access to affordable medications and adherence support. Socioeconomic challenges, such as low income and lack of insurance, further impede participation in adherence programs. These barriers reduce enrolment and engagement, thereby restricting the effectiveness and growth potential of these programs.

Regulatory Landscape and Reimbursement Scenario

In Mexico, the Federal Commission for Protection against Health Risks (COFEPRIS or Comisión Federal para la Protección contra Riesgos Sanitarios) is a regulatory body of the Mexican Government; a decentralized organ of the Mexican Secretariat of Health. Among the many health-related issues it regulates in Mexico are pharmaceuticals, food safety, medical devices, organ transplants, and environmental preservation. COFEPRIS is in charge of the entire drug approval process, from the initial application to the post-market surveillance (PMS) stage, including supply and demand, advertising, commercialization, imports and exports, distribution, manufacturing, and supply.

Mexico’s pharmaceutical industry is thriving and expanding, and thus strict laws are in place to guarantee the security and effectiveness of medications made available to Mexican residents. Pharmaceutical companies seeking to sell their medications in Mexico must understand the procedure thoroughly to get approval. The overall approval includes an extensive evaluation by COFEPRIS, accompanied by facility inspection to ensure GMP compliance. There are three different pathways for registering medicinal products with COFEPRIS. The New Drug Registration is the pathway applicable for new chemical entities that have not previously been marketed anywhere in the world. Next, is the Generic Drug Registration for drugs that are similar to the already-marketed reference drugs. Lastly, Biosimilar Registration is applicable to biological products that are similar to the approved reference biological product.

The healthcare reimbursement system in Mexico is characterized by a complex interplay between the public and private sectors. For the public sector, social security institutions are the main provider of public health insurance. Workers in the formal sector and their dependents are covered by the Instituto Mexicano del Seguro Social (IMSS). Government employees and their families are covered by the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE). To supplement public plans with extra coverage, many Mexicans opt to buy private health insurance which provides access to a greater variety of healthcare providers, such as private hospitals and specialists. The healthcare reimbursement scheme in Mexico is gradually evolving. Although many people have a safety net in public services, there are still large differences. In the future, there may be initiatives to increase public-private partnerships, achieve universal coverage, and use technology to improve healthcare affordability and accessibility for all.

Competitive Landscape

Key Players

Here are some of the major key players in the Mexico Patient Adherence Programs Market:

• Grupo Neolpharma
• PiSA Farmaceutica
• Liomont
• Laboratorios Sanfer
• Laboratorios Sophia
• Genomma Lab Internactional
• Laboratorios Silanes
• Profarma
• Landsteiner Scientific
• Carnot Laboratories